Literature DB >> 16533542

Adenoviral vectors--how to use them in cancer gene therapy?

Dragomira Majhen1, Andreja Ambriović-Ristov.   

Abstract

Gene therapy is most often described as a technique for introducing the foreign genetic material into cells with a correction of a dysfunctional gene as its final goal. Today, it is well known that cancer is one of the leading causes of mortality in the world. Besides classical methods for cancer treatment new strategies against cancer are needed. Although originally being designed as a treatment for monogenetic illness, soon after, gene therapy appeared as a potential new strategy in cancer therapy. One of the widely used vectors for cancer gene therapy is adenovirus. In this review we have described molecular biology of adenoviruses and basis for construction of adenoviral vectors. We have also described concepts for cancer gene therapy including their in vitro and in vivo application. Special attention is drawn toward retargeting of adenovirus as a new approach in vector design for cancer gene therapy, in order to restrict transgene expression in tumor tissue. This approach uses biophysical as well as genetic characteristics of tumor itself and its supporting tissue, allowing new "bypass" in cancer gene therapy.

Entities:  

Mesh:

Year:  2006        PMID: 16533542     DOI: 10.1016/j.virusres.2006.02.001

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  11 in total

Review 1.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

2.  Expression of HIF-1α ODD domain fused canine caspase 3 by EGFR promoter-driven adenovirus vector induces cytotoxicity in canine breast tumor cells under hypoxia.

Authors:  Mariko Okamoto; Ai Asamura; Ko Tanaka; Takefumi Soeda; Kyo Watanabe; Hiroyuki Mizuguchi; Teruo Ikeda
Journal:  Vet Res Commun       Date:  2016-10-16       Impact factor: 2.459

3.  Resistance of canine lymphoma cells to adenoviral infection due to reduced cell surface RGD binding integrins.

Authors:  Ann Marie O'Neill; Annette N Smith; Elizabeth A Spangler; Elizabeth M Whitley; Stephanie E Schleis; Richard C Bird; David T Curiel; Erin E Thacker; Bruce F Smith
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

Review 4.  Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?

Authors:  Catherine Tang; Pamela J Russell; Rosetta Martiniello-Wilks; John E J Rasko; Aparajita Khatri
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

5.  Silencing of FOXM1 transcription factor expression by adenovirus-mediated RNA interference inhibits human hepatocellular carcinoma growth.

Authors:  T Chen; J Xiong; C Yang; L Shan; G Tan; L Yu; Y Tan
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

6.  Cell-specific expression of artificial microRNAs targeting essential genes exhibit potent antitumor effect on hepatocellular carcinoma cells.

Authors:  Chenyu Mao; Hao Liu; Ping Chen; Jingjia Ye; Lisong Teng; Zhenyu Jia; Jiang Cao
Journal:  Oncotarget       Date:  2015-03-20

7.  Production of human epidermal growth factor using adenoviral based system.

Authors:  Babak Negahdari; Zahra Shahosseini; Vahid Baniasadi
Journal:  Res Pharm Sci       Date:  2016 Jan-Feb

Review 8.  Adenovirus receptors and their implications in gene delivery.

Authors:  Anurag Sharma; Xiaoxin Li; Dinesh S Bangari; Suresh K Mittal
Journal:  Virus Res       Date:  2009-02-26       Impact factor: 3.303

9.  Microencapsulation of PEGylated adenovirus within PLGA microspheres for enhanced stability and gene transfection efficiency.

Authors:  Hyejung Mok; Ji Won Park; Tae Gwan Park
Journal:  Pharm Res       Date:  2007-10-11       Impact factor: 4.580

10.  Construction and characterization of an adenoviral vector encoding human bone morphogenetic protein-2.

Authors:  Liangquan Peng; Kang Chen; Weimin Zhu; Wei Lu; Jian Xu; Yong Huang; Shengzheng Kuai; Zhenhan Deng; Daping Wang
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.